Heart Failure With Reduced Ejection Fraction Clinical Trial
Official title:
The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Reduced Ejection Fraction - a Randomized Controlled Trial
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding their efficacy and safety in patients under chronic hemodialysis. As the primary target of SGLT2i is expressed mostly in the kidneys, the efficacy of SGLT2i in patients with ESRD may be limited. On the other hand, patients with ESRD are at higher risks of experiencing cardiovascular events and may still benefit from treatment. Several mechanistic studies have demonstrated direct actions of SGLT2i on the myocardium, thus it is possible that the benefits of SGLT2i on heart failure are independent of their glycosuric actions and may still be present in anuric subjects. Furthermore, pharmacokinetics and pharmacodynamics studies on empagliflozin demonstrated that peak plasma levels of empagliflozin in subjects with renal failure/ESRD were similar to those in subjects with normal renal function. The use of empagliflozin in patients with ESRD seemed safe in terms of pharmacokinetics and pharmacodynamics, yet its efficacy remains to be explored.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
| Completed |
NCT03614169 -
Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB
|
N/A | |
| Recruiting |
NCT05278962 -
HF Patients With LVADs Being Treated With SGLT2i
|
Phase 4 | |
| Completed |
NCT04210375 -
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
|
Phase 1 | |
| Not yet recruiting |
NCT06433687 -
Evaluation of the HekaHeart Platform in Medication Management for Heart Failure Patients
|
||
| Completed |
NCT05001165 -
Dashboard Activated Services and Tele-Health for Heart Failure
|
N/A | |
| Active, not recruiting |
NCT03701880 -
Early Use of Ivabradine in Heart Failure
|
N/A | |
| Recruiting |
NCT05650658 -
Left vs Left Randomized Clinical Trial
|
N/A | |
| Not yet recruiting |
NCT06299436 -
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
|
||
| Recruiting |
NCT05992116 -
Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
|
||
| Recruiting |
NCT05365568 -
Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: A Randomized Study
|
N/A | |
| Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
| Not yet recruiting |
NCT04420065 -
Effects of Preferential Left Ventricular Pacing on Ventriculoarterial Coupling and Clinical Course of Heart Failure
|
N/A | |
| Terminated |
NCT03479424 -
Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
|
||
| Completed |
NCT02113033 -
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
|
Phase 2 | |
| Recruiting |
NCT03209180 -
Immediate Release Versus Slow Release Carvedilol in Heart Failure
|
Phase 4 | |
| Recruiting |
NCT05299879 -
Screening for Advanced Heart Failure IN Stable ouTpatientS - The SAINTS Study
|
||
| Recruiting |
NCT05637853 -
Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
|
||
| Completed |
NCT03870074 -
CPET Predicts Long-term Survival and Positive Response to CRT
|
||
| Recruiting |
NCT04590001 -
Effect of the MobiusHD® in Patients With Heart Failure
|
N/A |